Eli Lilly and Company (LLY)vsTenaya Therapeutics Inc (TNYA)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
TNYA
Tenaya Therapeutics Inc
$0.69
+4.66%
HEALTHCARE · Cap: $149.97M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TNYA
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : TNYA
The strongest argument for TNYA centers on Price/Book, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : TNYA
The primary concerns for TNYA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while TNYA is a value play — different risk/reward profiles.
TNYA carries more volatility with a beta of 3.00 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 28/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Tenaya Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tenaya Therapeutics Inc. is a pioneering clinical-stage biotechnology company focused on transforming the treatment landscape for heart disease through its proprietary engineered heart cell platform. With a robust pipeline of innovative gene therapies and regenerative solutions, Tenaya addresses critical unmet needs in cardiovascular medicine, positioning itself for substantial growth within the biopharmaceutical sector. The company's commitment to scientific rigor and patient-centered outcomes makes it an attractive investment opportunity for institutional investors looking to support the advancement of cardiac care. Tenaya's strategic initiatives reflect its potential to make significant contributions to the evolving market for cardiovascular therapies, highlighting its role as a leader in biomedical innovation.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?